$DXCM

Brown Michael Jon sold $128K of DXCM

Brown Michael Jon (EVP Chief Legal Compliance Off) sold 1,700 shares of DEXCOM INC (DXCM) at $75.55 ($0.13M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brown Michael Jon
Published Jun 17, 2026, 8:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 8:51 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DXCM
Neutral
high confidence
Mentioned
$DXCM
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DXCMNeutralLow
01

Why it matters

This is a disclosed officer sale under a pre-arranged 10b5-1 plan; absent any new company-specific fundamentals, it is mainly sentiment/positioning information rather than a catalyst.

02

Market read

Traders may monitor insider activity, but the 10b5-1 structure and lack of additional disclosures suggest limited tradable impact.

03

What to watch

The article provides only the sale size and price; it does not indicate whether there were concurrent buys, changes in compensation, or broader company developments that could contextualize the transaction.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-17; sale executed 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for DexCom, filed via EDGAR.

Company-level read

Ticker impact

$DXCMNeutralHigh confidence
Context

DexCom insider Form 4 shows EVP Chief Legal Compliance Officer Brown sold 1,700 shares at $75.55 on 2026-06-15 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any effect is likely brief and sentiment-driven.

Evidence & confidence

The filing is a disclosed open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational or financial catalyst in the text.

Market effects

Minimal read-through to medical device/diabetes tech peers because this is a single-company insider transaction without new fundamentals.

No clear regional spillover implied by the filing details provided.

Limited global relevance; insider sale disclosure is company-specific and not tied to international operations in the text.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild caution signal, especially if it coincides with other negative news not mentioned here.

Key entities

  • DexCom

    Subject of the SEC Form 4 insider transaction disclosure.

  • Brown Michael Jon

    EVP Chief Legal Compliance Officer who sold 1,700 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DXCMHighAI 8/10

DexCom stock hits 52-week high at 91.99 USD

DexCom Inc (DXCM) stock reached a 52-week high of $92.01, with a 36% year-to-date return. The company reported Q2 revenue of $1.308B, up 13% YoY, and raised its financial guidance. Analysts increased price targets, with Piper Sandler setting a $95 target. DexCom's inclusion in the FDA's TEMPO program and a perfect Piotroski Score of 9 indicate strong financial health.

$DXCMMed

Is Wall Street Bullish or Bearish on DexCom Stock?

DexCom (DXCM) designs continuous glucose monitoring systems. The stock lagged the S&P 500 and XLV over 52 weeks but gained 37.2% YTD. After Q2 2026 results on Jul. 30, adjusted EPS was $0.70 and revenue $1.31B, up 13% YoY, beating estimates. DexCom raised 2026 revenue guidance to $5.18B-$5.25B. Canaccord lifted its price target to $90; mean target $92.48.